Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/01/23
End: 02/01/24
Due: 02/01/25
Phase: N/A
Priority: Normal
Start: 02/01/21
End: 01/31/24
Due: 01/31/25
Phase: N/A
Priority: Normal
Start: 11/30/14
End: 05/18/18
Due: 05/18/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection | NCT05669261 | American CryoStem Corporation | user2@example.com | None | 2023-08-01 | 2024-02-01 | 2025-02-01 | - | - | 2025-07-14 |
| ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion | NCT04744051 | American CryoStem Corporation | user2@example.com | None | 2021-02-01 | 2024-01-31 | 2025-01-31 | - | - | 2025-07-14 |
| Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis | NCT02326935 | American CryoStem Corporation | user2@example.com | None | 2014-11-30 | 2018-05-18 | 2019-05-18 | - | - | 2025-07-14 |